New CLL strategy: give extra drug only to those who still have cancer cells
NCT ID NCT05650723
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a personalized approach for chronic lymphocytic leukemia (CLL). Patients first receive two oral drugs (zanubrutinib and venetoclax). Only those who still have detectable cancer cells after treatment get an additional infusion drug (obinutuzumab). The goal is to see if this strategy can clear cancer while avoiding unnecessary side effects. About 50 adults with CLL are enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zanubrutinib, venetoclax, and obinutuzumab
- What this could lead to
- If successful, this approach could reduce side effects by giving fewer drugs to more patients, while still effectively controlling CLL.
- What could go wrong
- This is a small, early-phase trial (50 people) with no control group. The strategy may not work for everyone, and side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weill Cornell Medicine/NewYork-Presberteryian Hospital
New York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New BTK blocker aims to outsmart drug resistance in elderly CLL patients
- New combo aims to shorten CLL treatment
- New pill shows promise against Hard-to-Treat blood cancers
- New hope for tough blood cancers: early trial of ONO-7018 begins
- New cocktail aims to tame Slow-Growing blood cancers
- New combo therapy for CLL tested in Real-World settings